DocumentRX-2253
Issued
Read4 min

Wegovy pill holds 72.8% of oral obesity market as Foundayo scripts hit record

Wegovy pill holds 72.8% of the oral obesity market at week 42 with 185K scripts; Foundayo hits a record 69K but trails Novo's launch pace by half. Q3 sales: $811M vs $184M.

TAG V-8604 · 825 words on the filing

The Oral GLP-1 Tracker: Foundayo, Wegovy pill keep scripts on the ascent - Fierce Pharma
The Oral GLP-1 Tracker: Foundayo, Wegovy pill keep scripts on the ascent - Fierce PharmaFoYu / pixabay

Summary of findings

  • Week 42: Wegovy pill at 185K scripts, 72.8% oral market share; Foundayo at 69K, 27.2% (Jefferies/IQVIA, Nov. 13, 2026).
  • Q3 sales: Wegovy pill DKK 5.39 billion (~$811M); Foundayo $184M, missing consensus by $50M.
  • Foundayo drives ~40% of new oral obesity prescriptions and 45% of incremental oral market growth (Jefferies).
  • EMA recommended EU approval for Foundayo in weight management and Type 2 diabetes; EC decision expected within weeks.
  • Medicare GLP-1 Bridge ($50 copay) launched July 1; Lilly cut Foundayo starting-dose self-pay prices to $149-$199 on Sept. 1.

Novo Nordisk's Wegovy pill commanded 72.8% of the U.S. oral obesity market in week 42 of its rollout, while Eli Lilly's Foundayo posted its strongest week yet at 69,000 prescriptions — a 7% week-over-week jump, according to Citi and Jefferies notes citing IQVIA data.

The gap remains structural. At week 31 of its own launch, the Wegovy pill recorded 163,000 scripts; Foundayo needed 25 weeks to reach what oral semaglutide achieved in seven. Yet Jefferies now credits Foundayo with roughly 40% of new oral obesity prescriptions and 45% of the market's incremental growth. Week 42 prescriptions for the Wegovy pill climbed slightly to 185,000.

What does the share shift mean for revenue?

The Q3 numbers frame the stakes. Novo reported 5.39 billion Danish kroner (nearly $811 million) in third-quarter Wegovy pill sales. Lilly booked $184 million for Foundayo over the same period, including $124 million from the U.S. — a $50 million miss against consensus, per Jefferies.

Lilly's stock nonetheless jumped on earnings day. Jefferies analysts wrote that investors are "increasingly focusing on the breadth and depth of [Lilly]'s obesity franchise rather than near-term Foundayo [numbers]," as both tirzepatide products, Mounjaro and Zepbound, beat Wall Street projections.

Lilly's CFO noted on the Q3 call that roughly 4 in 10 patients starting an oral obesity medicine choose Foundayo, and that new Foundayo patients doubled quarter over quarter.

Is IQVIA undercounting Novo — or Lilly?

Both companies have challenged the data. Novo's EVP of U.S. operations, Jamey Millar, told analysts that Novo boasts "a much more extensive ecosystem of partners for Wegovy" than Lilly, and that those partners "don't report to IQVIA in absolute terms."

"So we've consistently seen a lower capture rate for Wegovy pill than the competitive oral product," he said.

Citi has repeatedly flagged the mirror-image problem on Lilly's side: telehealth prescriptions for Foundayo may be missing from IQVIA. Lilly executives said in April that telehealth platforms generated some 35% of launch volume, with 45% of scripts flowing through LillyDirect and 20% through retail.

How did Foundayo build from a muted start?

The launch was flat through June, hovering near 20,000 weekly scripts — Jefferies called it "muted" — with CVS Caremark the last of the big three PBMs to add coverage, starting June 1. Wegovy pill, by contrast, had full PBM coverage in its first launch week.

The inflection arrived in July, coinciding with the Medicare GLP-1 Bridge program, which went live July 1 offering eligible seniors GLP-1 obesity drugs at a $50 monthly copay. Lilly president Ilya Yuffa said the company was "starting to see an inflection point on Foundayo now."

Lilly also cut self-pay initial-dose pricing effective Sept. 1 — $149 for the 0.8 mg and 2.5 mg doses, $199 for 5.5 mg — which Leerink Partners framed as an elasticity experiment. A direct-to-consumer ad featuring Martha Stewart first aired in late August. Jefferies noted about 80% of Foundayo patients remain on starting doses, mostly cash-pay.

CEO David Ricks told CNBC that Foundayo now captures about 1 in 3 new oral GLP-1 starts, "and that's growing week over week." In the Medicare Bridge program, Lilly captures 7 of 10 patients, most on Zepbound; Ricks said Foundayo draws Medicare patients seeking convenience over maximal weight loss.

What does this change for the broader market?

Orals are expanding the class, not just splitting it. Citi measured total GLP-1 prescriptions up 5.4% over four weeks in September, versus a 6.8% decline a year earlier — a 12-percentage-point swing attributed to oral launches. More than 80% of new Wegovy pill prescriptions come from patients new to GLP-1 therapy, Novo reported.

In injectables, Zepbound leads with about 801.8K weekly scripts against roughly 492.6K for all Wegovy formulations. Tirzepatide holds a 57% share of the total GLP-1 market, up from 49.5% last year; semaglutide sits near 37%.

Geographic expansion is next. The EMA recommended EU marketing authorization for Foundayo in weight management and Type 2 diabetes on Oct. 13, with European Commission sign-off expected within weeks. Jefferies sees the real Foundayo opportunity ex-U.S., citing "clear advantages on scale, distribution and [cost of goods sold]." A J.P. Morgan estimate reported by Reuters puts GLP-1 markets in China, India and Brazil growing from $6.6 billion now to $22 billion by the mid-2030s.

Sandoz, meanwhile, has secured FDA acceptance of its generic tirzepatide autoinjector applications covering all Mounjaro and Zepbound indications — a variable that could reshape the oral-versus-injectable calculus.

Novo needed just over five months to log 3 million Wegovy pill prescriptions — one fill roughly every five seconds, by the company's own count. Foundayo's job now is to prove it can convert share of new starts into share of the franchise.

via Fierce Pharma (Google News) (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

22 articles

Linked filings

  1. K-4995
  2. K-4629
  3. K-1191
  4. T-7183
  5. E-6328

« Previous filingNext filing »